Phase II trial of the histone deacetylase inhibitor Belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumors

AIM: Micropapillary/borderline (LMP) ovarian tumors are rarely included in clinical trials and are intrinsically resistant to radiation and chemotherapy. Platinum resistant epithelial ovarian cancer (EOC) has a poor prognosis. The histone deacetylase inhibitor belinostat demonstrated antitumor activ...

Full description

Saved in:
Bibliographic Details
Main Authors: Mackay, Helen J., Hirte, Hal, Colgan, Terrence, Covens, Al, MacAlpine, Katrina, Grenci, Pamela, Wang, Lisa, Mason, Jaqueline, Pham, Pnu-An, Tsao, Ming-S, Pan, James, Zwiebel, James, Oza, Amit M.
Format: Artigo
Language:Inglês
Published: 2010
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3244274/
https://ncbi.nlm.nih.gov/pubmed/20304628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2010.02.047
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items